Zobrazeno 1 - 10
of 534
pro vyhledávání: '"Carol Aghajanian"'
Autor:
Razvan Cristescu, Andrey Loboda, Robert Orlowski, Vicky Makker, Matthew H Taylor, Carol Aghajanian, Petar Jelinic, Lea Dutta, Allen L Cohn, Marcia S Brose, Christopher Di Simone, Zhu Alexander Cao, Leah Suttner, Junji Matsui, Corina E Dutcus, Yukinori Minoshima, Mark J Messing
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated
Externí odkaz:
https://doaj.org/article/1aba98f370d441fabd9fdd926cef1538
Autor:
Sushmita B. Gordhandas, Beryl Manning-Geist, Christina Henson, Gopa Iyer, Ginger J. Gardner, Yukio Sonoda, Kathleen N. Moore, Carol Aghajanian, M. Herman Chui, Rachel N. Grisham
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-6 (2022)
Abstract DNA-dependent protein kinase (DNA-PK) plays a crucial role in repair of DNA double-strand breaks by facilitating non-homologous end-joining. Inhibitors of DNA-PK have the potential to block DNA repair and enhance DNA-damaging agents. Peposer
Externí odkaz:
https://doaj.org/article/1d9198557bb64facb89982452a6009a5
Autor:
Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7162-7173 (2021)
Abstract Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease. Methods Patients were randomized 2:1 to rec
Externí odkaz:
https://doaj.org/article/2cbcf9c399a94021b6832bbcf96e807d
Autor:
Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 c
Externí odkaz:
https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
Autor:
Beryl L. Manning-Geist, Sacha Gnjatic, Carol Aghajanian, Jason Konner, Sarah H. Kim, Debra Sarasohn, Krysten Soldan, William P. Tew, Nicholas J. Sarlis, Dmitriy Zamarin, Sara Kravetz, Ilaria Laface, Teresa Rasalan-Ho, Jingjing Qi, Phillip Wong, Paul J. Sabbatini, Roisin E. O’Cearbhaill
Publikováno v:
Cancers, Vol 15, Iss 5, p 1458 (2023)
We examined the safety and immunogenicity of sequential administration of a tetravalent, non-HLA (human leukocyte antigen) restricted, heteroclitic Wilms’ Tumor 1 (WT1) peptide vaccine (galinpepimut-S) with anti–PD-1 (programmed cell death protei
Externí odkaz:
https://doaj.org/article/2fae61eec6c7477bab9bf0842ed06642
Autor:
Elizabeth H. Stover, Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak, Russell R. Broaddus, Vicky Makker, Ronny Drapkin, Joyce F. Liu, Neil S. Horowitz, Funda Meric-Bernstam, Carol Aghajanian, Robert L. Coleman, Gordon B. Mills, Lewis C. Cantley, Ursula A. Matulonis, Shannon N. Westin, Panagiotis A. Konstantinopoulos
Publikováno v:
Gynecologic Oncology Reports, Vol 40, Iss , Pp 100974- (2022)
Uterine serous carcinoma (USC) is an uncommon subtype of endometrial cancer with a poor prognosis. USCs have genomic alterations in the PI3K pathway. A prior phase II study of AKT inhibitor MK-2206 (an allosteric AKT inhibitor, primarily affecting AK
Externí odkaz:
https://doaj.org/article/9a6dad8bf1b54f1fada0cfe8b5c09232
Autor:
Harini Veeraraghavan, Claire F. Friedman, Deborah F. DeLair, Josip Ninčević, Yuki Himoto, Silvio G. Bruni, Giovanni Cappello, Iva Petkovska, Stephanie Nougaret, Ines Nikolovski, Ahmet Zehir, Nadeem R. Abu-Rustum, Carol Aghajanian, Dmitriy Zamarin, Karen A. Cadoo, Luis A. Diaz, Mario M. Leitao, Vicky Makker, Robert A. Soslow, Jennifer J. Mueller, Britta Weigelt, Yulia Lakhman
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Abstract To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs). Patients who underwent targete
Externí odkaz:
https://doaj.org/article/039f6ea3eee241349cd91ff919a41db5
Autor:
Emmett Schmidt, Matthew Taylor, Allen Cohn, Corina Dutcus, Marcia Brose, Robert Orlowski, Jie Huang, Carol Aghajanian, Margarita Romeo, Raquel Bratos, Mark Messing, Lea Dutta
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/25fb2fd9e17d4770b2699ba5010504c8
Autor:
Kathryn M. Miller, Olga T. Filippova, Sara A. Hayes, Nadeem R. Abu-Rustum, Carol Aghajanian, Vance Broach, Lora H. Ellenson, Pier Selenica, Elizabeth L. Jewell, Chrisann Kyi, Yuliya Lakhman, Jennifer J. Mueller, Roisin E. O'Cearbhaill, Kay J. Park, Yukio Sonoda, Dmitriy Zamarin, Britta Weigelt, Mario M. Leitao, Jr, Claire F. Friedman
Publikováno v:
Gynecologic Oncology Reports, Vol 37, Iss , Pp 100831- (2021)
Objective: Since the approval of pembrolizumab for advanced or recurrent PD-L1 positive (CPS > 1%) cervical cancer, the clinical characteristics associated with response have remained undefined. We sought to characterize the clinicopathologic feature
Externí odkaz:
https://doaj.org/article/f9fa330185344c4388e2ef3b496eba95
Autor:
Chrisann Kyi, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, Ekaterina Doubrovina, Sara Kravetz, David Spriggs, Richard J O'Reilly, Roisin E O’Cearbhaill
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/f7056119a4df4d95a6126042111a2959